Stimunity is focused on developing innovative therapies that leverage the STING (Stimulator of Interferon Genes) pathway to enhance the innate immune response against cancer and infectious diseases. Their unique approach utilizes STING-activating Virus-Like Particles (VLPs) to stimulate the immune system, particularly targeting dendritic cells, which play a crucial role in presenting tumor antigens. This targeted activation is designed to improve the efficacy of existing immunotherapies, particularly immune checkpoint inhibitors, which currently benefit only a small percentage of patients. By enabling systemic administration of their therapies, Stimunity aims to facilitate multiple treatment rounds and broaden the therapeutic applications across various tumor types.

The scientific foundation of Stimunity's technology is rooted in high-level academic research from esteemed institutions, including Institut Curie, Inserm, and the University of Oxford. Their preclinical studies have demonstrated that STING activation can elicit a robust T cell response against tumors, potentially restoring the effectiveness of immune checkpoint inhibitors when used in combination. The company has secured significant funding, including seed investments and grants from the European Union’s Horizon 2020 program, to advance their research and development efforts toward clinical trials.

France

Stimunity is a preclinical-stage startup company which develops best-in-class drugs on the STING pathway to activate the innate immune system to fight back infectious pathogens or cancer. It was founded in 2016 and is focused on the development of STING agonists in cancer.

Stimunity

Company Details